Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenström's macroglobulinemia

Morie A. Gertz; Susan M. Geyer; Ashraf Badros; Brad S. Kahl; Charles Erlichman

doi:10.3816/CLM.2005.n.017

Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenström's macroglobulinemia

Morie A. Gertz, Susan M. Geyer, Ashraf Badros, Brad S. Kahl, Charles Erlichman

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. It prevents the expression of the bcl-2 gene product and leads to apoptosis in cells that express Bcl-2. bcl-2 is one of the major apoptosis regulatory gene families and is found in a variety of low-grade B-cell non-Hodgkin's lymphomas. The in vitro use of oblimersen in Waldenström's macroglobulinemia (WM) cell line results in enhanced toxicity when exposed to fludarabine, dexamethasone, or rituximab. Oblimersen should also enhance the cytotoxic effect of chemotherapy in WM. Presented herein are early data on the phase I portion of a phase I/II study of oblimersen in WM to identify the maximum tolerated dose and to evaluate response in patients with symptomatic WM.

Original language	English
Pages (from-to)	282-284
Number of pages	3
Journal	Clinical Lymphoma
Volume	5
Issue number	4
DOIs	https://doi.org/10.3816/CLM.2005.n.017
State	Published - Mar 2005

Keywords

Antisense oligonucleotide
Bcl-2
Low-grade B-cell non-Hodgkin's lymphoma
Neutropenia
Thrombocytopenia
Tumor lysis syndrome

Access to Document

10.3816/CLM.2005.n.017

Cite this

@article{4ff10368e22c4049a3f876ec42b6d7a3,

title = "Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstr{\"o}m's macroglobulinemia",

abstract = "Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. It prevents the expression of the bcl-2 gene product and leads to apoptosis in cells that express Bcl-2. bcl-2 is one of the major apoptosis regulatory gene families and is found in a variety of low-grade B-cell non-Hodgkin's lymphomas. The in vitro use of oblimersen in Waldenstr{\"o}m's macroglobulinemia (WM) cell line results in enhanced toxicity when exposed to fludarabine, dexamethasone, or rituximab. Oblimersen should also enhance the cytotoxic effect of chemotherapy in WM. Presented herein are early data on the phase I portion of a phase I/II study of oblimersen in WM to identify the maximum tolerated dose and to evaluate response in patients with symptomatic WM.",

keywords = "Antisense oligonucleotide, Bcl-2, Low-grade B-cell non-Hodgkin's lymphoma, Neutropenia, Thrombocytopenia, Tumor lysis syndrome",

author = "Gertz, {Morie A.} and Geyer, {Susan M.} and Ashraf Badros and Kahl, {Brad S.} and Charles Erlichman",

note = "Funding Information: This work was supported by National Cancer Institute N01-CM-17104.",

year = "2005",

month = mar,

doi = "10.3816/CLM.2005.n.017",

language = "English",

volume = "5",

pages = "282--284",

journal = "Clinical Lymphoma",

issn = "1526-9655",

number = "4",

}

TY - JOUR

T1 - Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenström's macroglobulinemia

AU - Gertz, Morie A.

AU - Geyer, Susan M.

AU - Badros, Ashraf

AU - Kahl, Brad S.

AU - Erlichman, Charles

N1 - Funding Information: This work was supported by National Cancer Institute N01-CM-17104.

PY - 2005/3

Y1 - 2005/3

N2 - Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. It prevents the expression of the bcl-2 gene product and leads to apoptosis in cells that express Bcl-2. bcl-2 is one of the major apoptosis regulatory gene families and is found in a variety of low-grade B-cell non-Hodgkin's lymphomas. The in vitro use of oblimersen in Waldenström's macroglobulinemia (WM) cell line results in enhanced toxicity when exposed to fludarabine, dexamethasone, or rituximab. Oblimersen should also enhance the cytotoxic effect of chemotherapy in WM. Presented herein are early data on the phase I portion of a phase I/II study of oblimersen in WM to identify the maximum tolerated dose and to evaluate response in patients with symptomatic WM.

AB - Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame. It prevents the expression of the bcl-2 gene product and leads to apoptosis in cells that express Bcl-2. bcl-2 is one of the major apoptosis regulatory gene families and is found in a variety of low-grade B-cell non-Hodgkin's lymphomas. The in vitro use of oblimersen in Waldenström's macroglobulinemia (WM) cell line results in enhanced toxicity when exposed to fludarabine, dexamethasone, or rituximab. Oblimersen should also enhance the cytotoxic effect of chemotherapy in WM. Presented herein are early data on the phase I portion of a phase I/II study of oblimersen in WM to identify the maximum tolerated dose and to evaluate response in patients with symptomatic WM.

KW - Antisense oligonucleotide

KW - Bcl-2

KW - Low-grade B-cell non-Hodgkin's lymphoma

KW - Neutropenia

KW - Thrombocytopenia

KW - Tumor lysis syndrome

UR - http://www.scopus.com/inward/record.url?scp=18144366606&partnerID=8YFLogxK

U2 - 10.3816/CLM.2005.n.017

DO - 10.3816/CLM.2005.n.017

M3 - Article

C2 - 15794866

AN - SCOPUS:18144366606

SN - 1526-9655

VL - 5

SP - 282

EP - 284

JO - Clinical Lymphoma

JF - Clinical Lymphoma

IS - 4

ER -

Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenström's macroglobulinemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this